LONDON and BOSTON, July 25, 2018: Morgan Lewis represented Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic or “cancer killing” immunotherapies for the treatment of solid tumors, in connection with its initial public offering of common stock and listing on the Nasdaq Global Select Market. Replimune’s common stock began trading under the ticker symbol REPL on July 20, 2018, and the offering closed on July 24, 2018.
The founders of Replimune were previously the management team of BioVex Group, a biotechnology company acquired by Amgen in 2011 for up to $1 billion. Morgan Lewis assisted the team in the formation of Replimune in the United Kingdom in 2015, and the company’s corporate migration to Massachusetts in 2017.
The Morgan Lewis team was led by partners Tim Corbett and Gitte Blanchet, from our London and Boston offices, respectively, with assistance from associates Ben Stein, Davis Truslow, and Rob Coniglio.